BR112016025312A2 - variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem - Google Patents

variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem

Info

Publication number
BR112016025312A2
BR112016025312A2 BR112016025312A BR112016025312A BR112016025312A2 BR 112016025312 A2 BR112016025312 A2 BR 112016025312A2 BR 112016025312 A BR112016025312 A BR 112016025312A BR 112016025312 A BR112016025312 A BR 112016025312A BR 112016025312 A2 BR112016025312 A2 BR 112016025312A2
Authority
BR
Brazil
Prior art keywords
composition
formulation
antibody
disorder
treating
Prior art date
Application number
BR112016025312A
Other languages
English (en)
Portuguese (pt)
Inventor
Tesar Devin
M Scheer Justin
Van Lookeren-Campagne Menno
E Hass Philip
F Kelley Robert
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112016025312A2 publication Critical patent/BR112016025312A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21046—Complement factor D (3.4.21.46)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112016025312A 2014-05-01 2015-04-30 variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem BR112016025312A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987298P 2014-05-01 2014-05-01
US201462076372P 2014-11-06 2014-11-06
PCT/US2015/028641 WO2015168468A1 (en) 2014-05-01 2015-04-30 Anti-factor d antibody variants and uses thereof

Publications (1)

Publication Number Publication Date
BR112016025312A2 true BR112016025312A2 (pt) 2017-10-17

Family

ID=53059539

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016025312A BR112016025312A2 (pt) 2014-05-01 2015-04-30 variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem

Country Status (19)

Country Link
US (1) US10179821B2 (enExample)
EP (1) EP3137503A1 (enExample)
JP (1) JP2017515811A (enExample)
KR (1) KR20160147855A (enExample)
CN (1) CN106536561A (enExample)
AU (1) AU2015253042A1 (enExample)
BR (1) BR112016025312A2 (enExample)
CA (1) CA2944712A1 (enExample)
CL (1) CL2016002738A1 (enExample)
CR (1) CR20160561A (enExample)
EA (1) EA201692109A1 (enExample)
IL (1) IL248042A0 (enExample)
MA (1) MA39934A (enExample)
MX (1) MX2016014160A (enExample)
PE (1) PE20161440A1 (enExample)
PH (1) PH12016502015A1 (enExample)
SG (1) SG11201608868PA (enExample)
TW (1) TW201623337A (enExample)
WO (1) WO2015168468A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US20170137535A1 (en) * 2015-10-30 2017-05-18 Genentech, Inc. Anti-factor d antibody formulations
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
GB2553252B (en) * 2016-01-20 2019-07-31 Vitrisa Therapeutics Inc Aptamers that block the catalytic cleft of complement Factor D
WO2017129064A1 (zh) * 2016-01-28 2017-08-03 成都康弘生物科技有限公司 抗补体因子D的人源化Fab和人源化抗体及其用途
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
AU2018217720A1 (en) * 2017-02-10 2019-09-05 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof
CN106905431B (zh) * 2017-04-10 2020-01-17 旭华（上海）生物研发中心有限公司 抗人补体d因子的单克隆抗体及其用途
EP3610010A4 (en) * 2017-04-14 2021-02-24 Kodiak Sciences Inc. COMPLEMENT FACTOR-D-ANTAGONIST-ANTIBODIES AND CONJUGATES THEREOF
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
BR112022022980A2 (pt) 2020-05-12 2022-12-20 Alexion Pharma Inc Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
JP2024515066A (ja) * 2021-04-09 2024-04-04 武田薬品工業株式会社 補体因子ｄを標的とする抗体及びその使用
WO2025045250A1 (en) * 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP2703764B2 (ja) 1986-04-28 1998-01-26 シータス オンコロジー コーポレイション 補体成分Ｃ５ａに対するモノクローナル抗体
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5244800A (en) 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
JPH08500826A (ja) 1992-08-21 1996-01-30 ジェネンテク，インコーポレイテッド Ｌｆａ−１仲介疾患を処置する方法
WO1994012219A2 (en) 1992-11-25 1994-06-09 Amgen Boulder Inc. Modified insulin-like growth factors
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
AU6626794A (en) 1993-04-07 1994-10-24 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5919623A (en) 1994-04-27 1999-07-06 St. James's And Seacroft University Hospitals Nhs Trust Nucleic acid mutation assays
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
WO2000037638A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US5681736A (en) 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
CA2302317A1 (en) 1997-08-26 1999-03-04 Gliatech, Inc. A process for inhibiting complement activation via the alternative pathway
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
EP1053245A4 (en) 1998-02-09 2002-04-17 Human Genome Sciences Inc 45 HUMAN SECRETED PROTEINS
PT1054693E (pt) 1998-02-20 2009-01-22 Genentech Inc Inibidores da activação do complemento
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
JP2002523089A (ja) 1998-08-27 2002-07-30 インサイト・ファーマスーティカルズ・インコーポレイテッド タンパク質輸送関連分子
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
IL142794A0 (en) 1998-12-16 2002-03-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
RU2244748C2 (ru) 1999-03-11 2005-01-20 РМФ Диктажен С.А. Адгезивные молекулы сосудов и модуляция их функций
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1234030A4 (en) 1999-11-19 2003-05-07 Human Genome Sciences Inc 18 HUMAN SECRETED PROTEINS
JP2004522404A (ja) 1999-12-01 2004-07-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
EP1253946A2 (en) 2000-02-10 2002-11-06 Alexion Pharmaceuticals, Inc. Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
EP1265929B1 (en) 2000-03-23 2009-07-08 Genentech, Inc. Anti-c2/c2a inhibitors of complement activation
ATE412185T1 (de) 2000-04-29 2008-11-15 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
AU2001271973A1 (en) 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2424379C (en) 2000-10-10 2013-10-01 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
SK5672003A3 (en) 2000-10-13 2003-10-07 Biogen Inc Humanized anti-LT-beta-R antibodies
JP4731793B2 (ja) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
US20040077575A1 (en) 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
CN100391537C (zh) 2001-08-17 2008-06-04 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
JP2005508162A (ja) 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
EP1556076A4 (en) 2002-06-24 2009-07-08 Genentech Inc APO-2 LIGAND / TRAIL VARIANTS AND ITS USES
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
US7595430B2 (en) 2002-10-30 2009-09-29 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
MXPA05008570A (es) 2003-02-21 2005-11-04 Tanox Inc Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion.
RU2232991C1 (ru) 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
EP2267028A3 (en) 2003-06-30 2011-07-27 Domantis Limited Dual specific single domain antibodies (dAb) conjugated to PEG
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US7923010B2 (en) 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
AU2005314461B2 (en) 2004-11-18 2012-02-02 The Rockefeller University Methods and compositions for treating ocular disorders
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP2319940A1 (en) 2005-01-04 2011-05-11 Hitachi Chemical Company, Ltd. Primer generation rolling circle amplification
NZ595305A (en) 2005-02-14 2013-06-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
NZ565659A (en) 2005-06-08 2010-03-26 Univ Pittsburgh Susceptibility genes for age-related maculopathy (ARM) on chromosome 10Q26
PL1951279T3 (pl) 2005-10-08 2017-12-29 Apellis Pharmaceuticals, Inc. Kompstatyna i jej analogi w zaburzeniach oczu
SI2500030T2 (sl) 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
WO2007113226A1 (en) 2006-03-31 2007-10-11 Novartis Ag Organic compounds
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
CN101541345A (zh) * 2006-09-25 2009-09-23 米迪缪尼有限公司 稳定化的抗体制剂和其应用
CA2663892A1 (en) * 2006-09-25 2008-04-03 Medimmune, Llc Stabilized antibody formulations and uses thereof
RS58233B1 (sr) 2006-11-02 2019-03-29 Genentech Inc Humanizovana anti-faktor d antitela i njihove upotrebe
JP2010526555A (ja) 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
MX2009012650A (es) * 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
WO2009029587A2 (en) 2007-08-24 2009-03-05 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
EP2283163B1 (en) 2008-04-18 2015-07-08 Tufts Medical Center Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009134709A2 (en) 2008-04-28 2009-11-05 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
AU2009264566B2 (en) 2008-06-25 2014-05-08 Novartis Ag Solubility optimization of immunobinders
CN101724144A (zh) 2008-11-03 2010-06-09 北京键凯科技有限公司 新型的多臂聚乙二醇及其制备方法和应用
EP2540843B1 (en) 2008-11-05 2014-07-02 Genentech, Inc. Genetic polymorphisms in age-related macular degeneration
WO2010075519A2 (en) 2008-12-23 2010-07-01 Massachusetts Eye & Ear Infirmary Allelic variants associated with advanced age-related macular degeneration
AU2009333100B2 (en) 2009-01-02 2014-08-14 Alcon Research, Ltd. In-situ refillable ophthalmic implant
WO2010085542A2 (en) 2009-01-23 2010-07-29 Novartis Ag Biomarkers related to age-related macular degeneration (amd)
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
WO2010132459A2 (en) 2009-05-11 2010-11-18 Cleveland Clinic Foundation Biomarkers for assessment of age-related macular degeneration
PT2449121T (pt) 2009-07-02 2020-09-21 Lanzatech New Zealand Ltd Processo de produção de álcool
EP2963128A1 (en) 2009-07-10 2016-01-06 The Regents of the University of Michigan Compositions and methods for diagnosing and treating macular degeneration
US20120190578A1 (en) 2009-08-06 2012-07-26 Washington University Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
CN102665759B (zh) * 2009-11-19 2015-09-30 默克雪兰诺有限公司 人源化抗il-22ra抗体
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
CN102108119A (zh) 2009-12-25 2011-06-29 天津键凯科技有限公司 多臂聚乙二醇衍生物及其与药物的结合物和凝胶
WO2012031273A2 (en) * 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
SI2635704T1 (sl) 2010-11-01 2017-07-31 F. Hoffmann-La Roche Ag Predvidevanje razvoja do napredne starostne makularne degeneracije s pomočjo poligenskega točkovanja
MX2013011706A (es) * 2011-04-07 2014-04-25 Amgen Inc Proteinas novedosas de enlace a antigeno.
LT2766393T (lt) 2011-10-14 2018-10-10 F. Hoffmann-La Roche Ag Antikūnai prieš htra1 ir jų naudojimo būdai
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
JP6051998B2 (ja) 2012-03-30 2016-12-27 日油株式会社 マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
EP3042205B1 (en) * 2013-09-06 2019-12-25 F. Hoffmann-La Roche AG Method for improving antibody stability
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.

Also Published As

Publication number Publication date
JP2017515811A (ja) 2017-06-15
EP3137503A1 (en) 2017-03-08
WO2015168468A1 (en) 2015-11-05
CN106536561A (zh) 2017-03-22
AU2015253042A2 (en) 2016-10-27
MA39934A (fr) 2017-03-08
PH12016502015A1 (en) 2017-01-16
SG11201608868PA (en) 2016-11-29
US10179821B2 (en) 2019-01-15
CL2016002738A1 (es) 2017-06-23
MX2016014160A (es) 2017-02-16
EA201692109A1 (ru) 2017-03-31
CR20160561A (es) 2017-05-03
TW201623337A (zh) 2016-07-01
KR20160147855A (ko) 2016-12-23
PE20161440A1 (es) 2017-01-26
CA2944712A1 (en) 2015-11-05
IL248042A0 (en) 2016-11-30
AU2015253042A1 (en) 2016-10-20
US20160017052A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
BR112018010018A2 (pt) moduladores de ror-gama
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
MX2016016380A (es) Composicion farmaceutica para usarse en la prevencion y/o tratamiento de enfermedades que se desarrollan o progresan como resultado de una disminucion o perdida de actividad del factor viii de coagulacion sanguinea activado.
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
BR112015006093A2 (pt) combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington
MX383759B (es) Composiciones farmacéuticas de il-2.
BR112018011607A2 (pt) composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico.
BR112016025876A2 (pt) composição, processos para preparar uma microcápsula e uma forma de dosagem unitária, forma de dosagem unitária, microcápsula, produto, uso de uma composição, e, método para tratar uma condição associada à vitamina k1 ou k2
MY199091A (en) Therapeutic compounds
MX2018004041A (es) Tratamiento de trastornos de acidos biliares.
CL2019000625A1 (es) Combinación de agonistas de fxr.
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
BR112017024714A2 (pt) métodos para preparação do fator de von willebrand modificado
BR112018013256A2 (pt) anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo
BR112017027285A2 (pt) ?cocristal, composição farmacêutica e método para o tratamento de uma doença?
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]